Pharma Firms Face Scrutiny Over Weight-Loss Drug Focus and Insulin Supply

The global pharmaceutical industry is under scrutiny as major pharmaceutical companies pivot their resources toward the high-profit market for weight-loss medications. While blockbuster GLP-1 drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have gained immense popularity in wealthy nations, experts warn this trend could threaten the supply of critical treatments for diabetes, particularly insulin.

According to a recent report by the Netherlands-based Access to Medicine Foundation, the intense focus on the obesity market risks diverting attention from the fundamental needs of patients with type 1 diabetes. Jay Iyer, the foundation’s chief executive, highlighted that while these medications are beginning to reach some low- and middle-income countries, the primary emphasis remains on weight loss rather than addressing the long-standing lack of access to insulin, a drug that has been available for over a century.

The Shift in Pharma Firms Priorities

The financial incentives driving this shift are significant. Pharmaceutical companies can command much higher prices and profit margins on weight-loss injections and pills compared to traditional diabetes medications. This economic reality has raised concerns that major manufacturers, including Sanofi, Eli Lilly, and Novo Nordisk, might eventually reduce their commitment to the insulin market. Such a move would be particularly devastating for patients in developing regions who rely on these drugs for survival.

The rush toward weight-loss drugs threatens the global supply of essential insulin for diabetes patients.

Global data shows that approximately 589 million adults live with diabetes, with 81% residing in low- and middle-income countries such as Egypt, Jordan, and Pakistan. Despite this, many of these regions struggle to secure basic insulin supplies. Furthermore, GLP-1 medications are often not registered in these areas, and when they are, the high costs and lack of equitable pricing strategies render them inaccessible to the majority of the population.

The Access to Medicine Foundation’s biennial report also noted that of the 25 medications currently in development within this therapeutic area, only 10 are specifically targeting type 1 diabetes. While some progress has been made in corporate strategy regarding medicine access, the current market dynamics heavily favor the lucrative obesity sector over the essential needs of those with chronic, insulin-dependent conditions.

Why it matters

This trend represents a growing divide in global healthcare equity. For millions of people in South Asia and other developing regions, the potential withdrawal of major firms from the insulin market could lead to a critical shortage of life-saving treatment.

As companies prioritize profitable weight-loss products, the most vulnerable populations, who already face barriers to accessing basic healthcare, may find themselves left behind in the global race for modern pharmaceutical innovation.